MedTrace Logo

Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome

NCT02968953 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2019-02-08

No results posted yet for this study

Summary

This treatment plan is intended for the use of UX007 (triheptanoin) in the treatment of a single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome.

Conditions

  • Glucose Transporter 1 Deficiency Syndrome

Interventions

DRUG

Triheptanoin

A single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome will receive tripheptanoin (UX007).

Sponsors & Collaborators

Principal Investigators

  • Gerard Vockley, MD, PhD · University of Pittsburgh

Eligibility

Min Age
3 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02968953 on ClinicalTrials.gov